Ziconotide Acetate
drug drugOn this page
Also known as PrialtSNX-111 ACETATE
Summary
Ziconotide Acetate (CHEMBL1795072) is an approved protein; indicated across 2 conditions.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Indications: 2 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1795072 |
| Name | Ziconotide Acetate |
| Type | Protein |
| Max phase | 4 |
Also known as: Prialt, SNX-111 ACETATE, Ziconotide acetate, ZICONOTIDE ACETATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00047749 | PHASE3 | COMPLETED | Prialt (Ziconotide) In Severe Chronic Pain |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.